Richmond Pharmacology is pleased to confirm our attendanceat the CPMR 2025 Symposium in London, a leading forum for advancing clinicalpharmacology and medical research.

This year’s symposium will gather distinguished clinicians,researchers, and industry partners to exchange insights on translationalmedicine, clinical innovation, and the future of early-phase research.

 

Representing Richmond Pharmacology:
Dr Jörg Täubel, Chief Executive Officer

 

Dr Täubel looks forward to engaging with peers andcollaborators to explore opportunities in:
• Early-phase clinical pharmacology research
• Innovative trial design and regulatory strategy
• Rare and metabolic disease studies
• Global-first patient recruitment models
• Adaptive and patient-centric clinical development

 

If you are attending CPMR 2025 and would like to learn how Richmond Pharmacology can support your clinical development programmes, we welcome you to connect with us during the event.

Latest news

Five Years Since a World-First CRISPR Breakthrough at Richmond Pharmacology

December 8, 2025
In November 2020, Richmond Pharmacology made medical history when a patient received the first-ever systemically delivered CRISPR therapy, using lipid nanoparticles to edit genes directly inside the human body.
Read more

Events

JSCPT 2025

5 – 6 December 2025
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
View event